Skip to main content
x

Recent articles

ASH 2024 preview – Arcellx disappoints

An ASH abstract reveals no delayed neurotoxicity, but three deaths, with anito-cel.

SITC 2024 preview – duelling TIGIT duds

Failed trials of vibostolimab and domvanalimab will be unveiled at SITC late-breakers.

Essa terminates an N-terminal journey

After beating "historical" Xtandi masofaniten fails to beat actual Xtandi.

FDA red and green lights: October 2024

October's US approvals included Scemblix, Vyloy and Itovebi, while Lumakras was delayed.

The month ahead: November’s upcoming events

Conferences ramp up, and ASH abstracts near.

No SOS for Bayer's SOS1

The group goes after a KRAS-related target on which Boehringer recently gave up.

Most Popular